Director/PDMR Shareholding

RNS Number : 5843Y

Oxford Biomedica PLC

22 August 2018

 

Director Dealings / Market Share Purchase

Oxford, UK - 22 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman of the Group, has purchased 302 ordinary shares of 50p each ("Ordinary Shares") in the Company on 22 August 2018 on the London Stock Exchange at a price of 880.54p per share as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.

Under the market share purchase agreement, one-third of Dr. Tallarigo's fees as Chairman, after tax, are to be used to purchase ordinary shares in Oxford BioMedica plc on a monthly basis at the prevailing market price.

Following this purchase Dr. Tallarigo holds 46,489 ordinary shares representing 0.07% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Lorenzo Tallarigo
2.	Reason for the notification
a.	Position/status	Chairman
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford BioMedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£8.8054	302
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	302  £8.8054  £2,659.23
f.	Date of the transaction	2018-08-22
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Group is 65,752,788 ordinary 50p shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson,  Chief Executive Officer Stuart Paynter, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

DSHBGGDIRUDBGID